Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Use of a fluorescent polarization based high throughput assay to identify new calmodulin ligands.

Dagher R, Pigault C, Bonnet D, Boeglin D, Pourbaix C, Kilhoffer MC, Villa P, Wermuth CG, Hibert M, Haiech J.

Biochim Biophys Acta. 2006 Nov;1763(11):1250-5. Epub 2006 Sep 26.

2.

Similarity in drugs: reflections on analogue design.

Wermuth CG.

Drug Discov Today. 2006 Apr;11(7-8):348-54. Review.

PMID:
16580977
3.

Selective optimization of side activities: the SOSA approach.

Wermuth CG.

Drug Discov Today. 2006 Feb;11(3-4):160-4. Review.

PMID:
16533714
4.

Multitargeted drugs: the end of the "one-target-one-disease" philosophy?

Wermuth CG.

Drug Discov Today. 2004 Oct 1;9(19):826-7. No abstract available.

PMID:
15381132
5.

Development of novel 1,2,3,4-tetrahydroisoquinoline derivatives and closely related compounds as potent and selective dopamine D3 receptor ligands.

Mach UR, Hackling AE, Perachon S, Ferry S, Wermuth CG, Schwartz JC, Sokoloff P, Stark H.

Chembiochem. 2004 Apr 2;5(4):508-18.

PMID:
15185375
6.

Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans.

Gaud A, Simon JM, Witzel T, Carre-Pierrat M, Wermuth CG, Ségalat L.

Neuromuscul Disord. 2004 Jun;14(6):365-70.

PMID:
15145337
7.

Selective optimization of side activities: another way for drug discovery.

Wermuth CG.

J Med Chem. 2004 Mar 11;47(6):1303-14. Review. No abstract available.

PMID:
14998318
8.

N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands.

Hackling A, Ghosh R, Perachon S, Mann A, Höltje HD, Wermuth CG, Schwartz JC, Sippl W, Sokoloff P, Stark H.

J Med Chem. 2003 Aug 28;46(18):3883-99.

PMID:
12930150
9.

A convenient 3-step synthesis of 3-acetamido-6-arylpyridazines directed to novel Y5 receptor antagonist.

Guéry S, Rival Y, Wermuth CG, Renard P, Boutin JA.

Chem Pharm Bull (Tokyo). 2002 May;50(5):636-9.

10.
11.

Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors.

Sippl W, Contreras JM, Parrot I, Rival YM, Wermuth CG.

J Comput Aided Mol Des. 2001 May;15(5):395-410.

PMID:
11394735
12.

Medicinal chemistry in the development of societies. Biodiversity and natural products.

Monge A, Chorghade M, Erhardt PW, Ganellin CR, Koga N, Lindberg P, Perun TJ, Topliss JG, Trivedi BK, Wermuth CG.

Eur J Med Chem. 2000 Dec;35(12):1121-5.

PMID:
11248411
13.

Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist.

Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P.

Nature. 1999 Jul 22;400(6742):371-5. Erratum in: Nature 1999 Sep 23;401(6751):403.

PMID:
10432116
14.

Aminopyridazines as acetylcholinesterase inhibitors.

Contreras JM, Rival YM, Chayer S, Bourguignon JJ, Wermuth CG.

J Med Chem. 1999 Feb 25;42(4):730-41.

PMID:
10052979
15.

5-HT3 antagonists derived from aminopyridazine-type muscarinic M1 agonists.

Rival Y, Hoffmann R, Didier B, Rybaltchenko V, Bourguignon JJ, Wermuth CG.

J Med Chem. 1998 Jan 29;41(3):311-7.

PMID:
9464362
16.

Modelling of the binding site of the human m1 muscarinic receptor: experimental validation and refinement.

Bourdon H, Trumpp-Kallmeyer S, Schreuder H, Hoflack J, Hibert M, Wermuth CG.

J Comput Aided Mol Des. 1997 Jul;11(4):317-32.

PMID:
9334899
17.

9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors.

Bourguignon JJ, Désaubry L, Raboisson P, Wermuth CG, Lugnier C.

J Med Chem. 1997 Jun 6;40(12):1768-70. No abstract available.

PMID:
9191951
18.

(2S,4S)-2-amino-4-(4,4-diphenylbut-1-yl)- pentane-1,5-dioic acid: a potent and selective antagonist for metabotropic glutamate receptors negatively linked to adenylate cyclase.

Wermuth CG, Mann A, Schoenfelder A, Wright RA, Johnson BG, Burnett JP, Mayne NG, Schoepp DD.

J Med Chem. 1996 Feb 16;39(4):814-6. No abstract available.

PMID:
8632404
19.

Functional models for the dopamine D3 receptor.

Griffon N, Sautel F, Pilon C, Lévesque D, Sokoloff P, Schwartz JC, Diaz J, Simon P, Costentin J, Mann A, Wermuth CG.

Biochem Soc Trans. 1996 Feb;24(1):193-8. Review. No abstract available.

PMID:
8674660
20.

Novel arylaminopyridazine-GABA receptor antagonists examined electrophysiologically in Ascaris suum.

Martin RJ, Sitamze JM, Duittoz AH, Wermuth CG.

Eur J Pharmacol. 1995 Mar 24;276(1-2):9-19.

PMID:
7781700
21.
22.
23.

Condensation of muscimol or thiomuscimol with aminopyridazines yields GABA-A antagonists.

Melikian A, Schlewer G, Chambon JP, Wermuth CG.

J Med Chem. 1992 Oct 30;35(22):4092-7.

PMID:
1331456
24.

Structure and molecular modeling of GABAA receptor antagonists.

Rognan D, Boulanger T, Hoffmann R, Vercauteren DP, Andre JM, Durant F, Wermuth CG.

J Med Chem. 1992 May 29;35(11):1969-77.

PMID:
1317920
25.

GABA-uptake inhibitors: construction of a general pharmacophore model and successful prediction of a new representative.

N'Goka V, Schlewer G, Linget JM, Chambon JP, Wermuth CG.

J Med Chem. 1991 Aug;34(8):2547-57.

PMID:
1831508
26.

Synthesis and biochemical evaluation of baclofen analogues locked in the baclofen solid-state conformation.

Mann A, Boulanger T, Brandau B, Durant F, Evrard G, Heaulme M, Desaulles E, Wermuth CG.

J Med Chem. 1991 Apr;34(4):1307-13.

PMID:
1849996
27.

Optically active benzamides as predictive tools for mapping the dopamine D2 receptor.

Rognan D, Sokoloff P, Mann A, Martres MP, Schwartz JC, Costentin J, Wermuth CG.

Eur J Pharmacol. 1990 Jul 31;189(1):59-70.

PMID:
1977603
28.

Anxiolytic and sedative properties of BW A78U, a novel anticonvulsant adenine derivative.

Willard M, Misslin R, Vogel E, Desaubry L, Wermuth CG, Bourguignon JJ.

Pharmacol Biochem Behav. 1990 Jan;35(1):85-8.

PMID:
1969166
29.

Pharmacological characterization of the aminopyridazine SR 95639A, a selective M1 muscarinic agonist.

Schumacher C, Steinberg R, Kan JP, Michaud JC, Bourguignon JJ, Wermuth CG, Feltz P, Worms P, Biziere K.

Eur J Pharmacol. 1989 Jul 18;166(2):139-47.

PMID:
2792188
30.

Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.

Marivet MC, Bourguignon JJ, Lugnier C, Mann A, Stoclet JC, Wermuth CG.

J Med Chem. 1989 Jul;32(7):1450-7.

PMID:
2544722
31.

3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.

Wermuth CG, Schlewer G, Bourguignon JJ, Maghioros G, Bouchet MJ, Moire C, Kan JP, Worms P, Biziere K.

J Med Chem. 1989 Mar;32(3):528-37.

PMID:
2563772
32.

Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies.

Bourguignon JJ, Schoenfelder A, Schmitt M, Wermuth CG, Hechler V, Charlier B, Maitre M.

J Med Chem. 1988 May;31(5):893-7.

PMID:
3361576
33.

The sensitivity of gamma-aminobutyric acid antagonists to thiocyanate is related to the absence of a functional anionic group in their structure.

Wermuth CG, Chambon JP, Heaulme M, Melikian A, Schlewer G, Leyris R, Biziére K.

Eur J Pharmacol. 1987 Dec 15;144(3):375-8.

PMID:
2831069
34.

Aryl diazo compounds and diazonium salts as potential irreversible probes of the gamma-aminobutyric acid receptor.

Bouchet MJ, Rendon A, Wermuth CG, Goeldner M, Hirth C.

J Med Chem. 1987 Dec;30(12):2222-7.

PMID:
2824775
35.

The active analog approach applied to the pharmacophore identification of benzodiazepine receptor ligands.

Tebib S, Bourguignon JJ, Wermuth CG.

J Comput Aided Mol Des. 1987 Jul;1(2):153-70.

PMID:
2848099
36.

Characterization of the binding of [3H]SR 95531, a GABAA antagonist, to rat brain membranes.

Heaulme M, Chambon JP, Leyris R, Wermuth CG, Biziere K.

J Neurochem. 1987 Jun;48(6):1677-86.

PMID:
3033146
37.

Synthesis and structure-activity relationships of a series of aminopyridazine derivatives of gamma-aminobutyric acid acting as selective GABA-A antagonists.

Wermuth CG, Bourguignon JJ, Schlewer G, Gies JP, Schoenfelder A, Melikian A, Bouchet MJ, Chantreux D, Molimard JC, Heaulme M, et al.

J Med Chem. 1987 Feb;30(2):239-49.

PMID:
3027337
38.

SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents.

Worms P, Kan JP, Wermuth CG, Roncucci R, Bizière K.

J Pharmacol Exp Ther. 1987 Jan;240(1):241-50.

PMID:
3100770
39.

A 7-phenyl substituted triazolopyridazine has inverse agonist activity at the benzodiazepine receptor site.

Biziere K, Bourguignon JJ, Chambon JP, Heaulme M, Perio A, Tebib S, Wermuth CG.

Br J Pharmacol. 1987 Jan;90(1):183-90.

40.

Dopamine-like activities of an aminopyridazine derivative, CM 30366: a behavioural study.

Worms P, Kan JP, Wermuth CG, Biziere K.

Naunyn Schmiedebergs Arch Pharmacol. 1986 Nov;334(3):246-52.

PMID:
3100965
41.

Specific binding of a phenyl-pyridazinium derivative endowed with GABAA receptor antagonist activity to rat brain.

Heaulme M, Chambon JP, Leyris R, Wermuth CG, Biziere K.

Neuropharmacology. 1986 Nov;25(11):1279-83.

PMID:
3025766
42.

Biochemical characterization of the interaction of three pyridazinyl-GABA derivatives with the GABAA receptor site.

Heaulme M, Chambon JP, Leyris R, Molimard JC, Wermuth CG, Biziere K.

Brain Res. 1986 Oct 8;384(2):224-31.

PMID:
3022866
43.

[Pharmacologic profile of an original psychotropic drug. Minaprine: comparison with six reference antidepressives].

Worms P, Kan JP, Perio A, Wermuth CG, Bizière K, Roncucci R.

J Pharmacol. 1986 Apr-Jun;17(2):126-38. French.

PMID:
3489135
44.

Synthesis and activity of 5-(aminomethylene)-1,3-cyclohexanediones: enolic analogues of gamma-aminobutyric acid.

Mann A, Humblet C, Chambon JP, Schlichter R, Desarmenien M, Feltz P, Wermuth CG.

J Med Chem. 1985 Oct;28(10):1440-6.

PMID:
2995665
45.

Photoaffinity labeling of D-2 dopamine binding subunits from rat striatum, anterior pituitary and olfactory bulb with a new probe, [3H]azidosulpride.

Redouane K, Sokoloff P, Schwartz JC, Hamdi P, Mann A, Wermuth CG, Roy J, Morgat JL.

Biochem Biophys Res Commun. 1985 Aug 15;130(3):1086-92.

PMID:
3161508
46.

Natural occurrence of trans-gamma hydroxycrotonic acid in rat brain.

Vayer P, Dessort D, Bourguignon JJ, Wermuth CG, Mandel P, Maitre M.

Biochem Pharmacol. 1985 Jul 1;34(13):2401-4. No abstract available.

PMID:
4015683
47.

gamma-Hydroxybutyrate uptake by rat brain striatal slices.

Hechler V, Bourguignon JJ, Wermuth CG, Mandel P, Maitre M.

Neurochem Res. 1985 Mar;10(3):387-96.

PMID:
4000394
48.

An arylaminopyridazine derivative of gamma-aminobutyric acid (GABA) is a selective and competitive antagonist at the GABAA receptor site.

Chambon JP, Feltz P, Heaulme M, Restle S, Schlichter R, Biziere K, Wermuth CG.

Proc Natl Acad Sci U S A. 1985 Mar;82(6):1832-6.

49.

The use of [3H](-)-DO 710 as selective dopaminergic ligand for binding and autoradiographic studies.

Sokoloff P, Brann M, Redouane K, Martres MP, Schwartz JC, Bouthenet ML, Sales N, Mann A, Hamdi P, Wermuth CG, et al.

Eur J Pharmacol. 1985 Jan 2;107(2):243-51.

PMID:
3979426
50.

Effects of taurine and taurine analogues on aggressive behavior.

Mandel P, Gupta RC, Bourguignon JJ, Wermuth CG, Molina V, Gobaille S, Ciesielski L, Simler S.

Prog Clin Biol Res. 1985;179:449-58. No abstract available.

PMID:
2865743

Supplemental Content

Loading ...
Support Center